Treatment for osteoporosis using growth hormone releasing factor (GRF) in combination with parathyroid hormone (PTH)
US5164368A · kind A · utility
32Cited by
2References
17Claims
0Family size
Inventor
Key dates
| Filing date | Nov 4, 1991 |
| Grant date | Nov 17, 1992 |
| Priority date | — |
| Expiry date | Nov 4, 2011 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method of treating osteoporosis, especially postmenopausal osteoporosis, by administering on a periodic but regular basis to a patient growth hormone releasing factor, GRF(1-44)-NH.sub.2, or a biologically active analog thereof, and concurrently administering parathyroid hormone, PTH(1-34)-NH.sub.2 and continuing the administration until bone mass increases and the patient's calcium balance becomes positive and indicates a mineral accumulation in the skeleton.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.